Jefferies Defends Epizyme (EPZM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
FDA AdCom Positive on Epizyme (EPZM) Tazemetostat
December 18, 2019 11:48 AM ESTFDA AdCom positive on Epizyme (NASDAQ: EPZM) Tazemetostat. 11 Yes votes that the benefits outweigh the risks. 0 No votes. (shares halted)
... MorePre-Open Movers 12/16: (AXSM) (INFN) (BMRN) Higher (WVE) (PCG) (BA) Lower (more...)
December 16, 2019 9:23 AM ESTToday's Pre-Open Movers
Axsome Therapeutics, Inc. (NASDAQ: AXSM) 78.5% HIGHER; announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary endpoint and rapidly and significantly improved symptoms of depression in the GEMINI Phase 3 trial in major depressive disorder (MDD). The GEMINI study was a randomized, double-blind, placebo-controlled, multi-center, U.S. trial, in which 327 adult patients with confirmed moderate to severe MDD were randomized to treatment with either AXS-05 (dextromethorphan/bupropion modulated delivery tablet) or placebo once daily for the first 3 days and twice... More
Epizyme (EPZM) on watch with FDA briefing documents released
December 16, 2019 8:24 AM ESTEpizyme (NASDAQ: EPZM) on watch with FDA briefing documents released (LINK)
... More